1. Home
  2. BTTC vs ACXP Comparison

BTTC vs ACXP Comparison

Compare BTTC & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTTC

Black Titan Corporation Ordinary Shares

HOLD

Current Price

$0.93

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.55

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTTC
ACXP
Founded
1990
2017
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0M
6.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BTTC
ACXP
Price
$0.93
$1.55
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$95.50
AVG Volume (30 Days)
115.9K
83.3K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$0.29
52 Week High
$11.22
$8.34

Technical Indicators

Market Signals
Indicator
BTTC
ACXP
Relative Strength Index (RSI) 55.28 47.00
Support Level $0.68 $1.36
Resistance Level $1.23 $1.75
Average True Range (ATR) 0.06 0.15
MACD 0.03 0.03
Stochastic Oscillator 69.70 39.81

Price Performance

Historical Comparison
BTTC
ACXP

About BTTC Black Titan Corporation Ordinary Shares

Black Titan Corp provides human resource and payroll consulting, software implementation, and training solutions using PeopleSoft platforms. The company's revenue is mainly derived from the provision of HCM solutions, followed by the provision of IT staff augmentation, outsourcing and consulting services.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: